The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01X | Other antineoplastic agents | |
| 4 | L01XL | Antineoplastic cell and gene therapy | |
| 5 | L01XL10 |
| Active Ingredient | Description | |
|---|---|---|
| Nadofaragene firadenovec |
Nadofaragene firadenovec is a non-replicating adenoviral vector-based gene therapy designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium. Intravesical instillation of nadofaragene firadenovec results in cell transduction and transient local expression of the IFNα2b protein that is anticipated to have anti-tumor effects. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ADSTILADRIN Suspension for intravesical instillation | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
